To detect the anticoagulation and antiplatelet effects of different concentrations of puerarin

heparin sodium and tirofiban hydrochloride on the blood samples of healthy volunteers by Sonoclot coagulation and platelet function analyzer. Peripheral blood samples were extracted from 20 healthy volunteers

followed by adding different concentrations of puerarin

heparin sodium and tirofiban hydrochloride. Samples were detected for activated clotting time (ACT)

clot rate (CR) and platelet function (PF) by Sonoclot coagulation and platelet function analyzer instrument. For puerarin and heparin sodium

the values of ACT gradually increased

and the values of CR and PF gradually decreased with increasing in drug concentration. There was a linear (or log linear) relationship between ACT

CR

PF value and drug concentration (P<0.01). Corresponding to each value

a regression equation was obtained. For tirofiban hydrochloride

the values of ACT and CR had no significant changes

while PF values gradually decreased with concentration increasing. There was also a linear relationship between PF values and concentrations of tirofiban hydrochloride (P<0.01). Under the same ACT values

the puerarin corresponding CR values (CR = e−0.0062ACT+4.31

P<2.2e-16) were always higher than the corresponding values (CR = e−0.0028ACT+2.79

P-value<2.2e-16) of heparin sodium. For high concentrations of puerarin (e.g. 3.8 mg/600 μL) and tirofiban hydrochloride (e.g. 0.8 μg/600 μL)

PF values had no significant difference. However

PF values for high puerarin concentration had a larger variance. Puerarin has similar anticoagulant and antiplatelet effects with the heparin sodium

and may have a lower hemorrhage risk than heparin sodium when obtained the same anticoagulation effect in the concentration range of this experiment. In addition

for high concentration

puerarin had the same antiplatelet function as tirofiban hydrochloride but with a larger individual variability.